ANLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Adlai Nortye Group Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 10, 2026

$10.38−0.65 (-5.89%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Adlai Nortye Group Ltd. cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation & Amortization	0.48	0.51	0.47	0.61	–
Stock-Based Compensation	1.53	2.45	4.33	6.08	3.39
Change in Accounts Payable	2.49	-4.20	1.25	10	0.60
Operating Cash Flow	-33	-52	-57	-43	-3.03
Capital Expenditures	-0.19	-0.17	-0.20	-1.25	-1.02
Sale of Property, Plant & Equipment	–	0.03	0.00	0.02	–
Investing Cash Flow	-16	28	-11	28	-55
Debt Issued	38	45	50	7.90	12
Debt Repaid	-40	-49	-24	-13	-10
Financing Cash Flow	-3.81	-6.58	116	-6.78	97
Foreign Exchange Rate Adjustments	0.00	-0.26	0.10	0.25	0.56
Free Cash Flow	-34	-52	-57	-44	-4.05

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: –
Operating margin: -714.0%
Net margin: -710.6%
Return on equity, FY2025: –

Financial strength

Current ratio: 0.65
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 19.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –